Bimekizumab shows long-term efficacy in hidradenitis suppurativa - PharmaTimes UCB's BIMZELX reveals promising two-year data at EHSF 2025

#Bimekizumab #hidradenitissuppurativa #dermatology #UCB #UCBPharma #BIMZELX #EHSF2025 #BEHEARDtrials #HiSCR75responders #interleukin17Ainhibitor #IL17Ainhibitor #interleukin17Finhibitor #IL17Finhibitor #EuropeanHidradenitisSuppurativaFoundation #HSpatients
pharmatimes.com/news/bimekiz...